WO1999053321A1 - Fixation d'une molecule biologique sur une surface d'un support - Google Patents
Fixation d'une molecule biologique sur une surface d'un support Download PDFInfo
- Publication number
- WO1999053321A1 WO1999053321A1 PCT/FR1999/000848 FR9900848W WO9953321A1 WO 1999053321 A1 WO1999053321 A1 WO 1999053321A1 FR 9900848 W FR9900848 W FR 9900848W WO 9953321 A1 WO9953321 A1 WO 9953321A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- support
- biological molecule
- specific binding
- protein
- binding site
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/552—Glass or silica
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/932—Specified use of nanostructure for electronic or optoelectronic application
- Y10S977/953—Detector using nanostructure
Definitions
- the present invention relates to a method of fixing a biological molecule, such as a recombinant protein derived from an antigen, an antibody, an enzyme, but also synthetic peptides and PNA (peptide nucleic acids), on the surface.
- a support consisting of silica or metal oxides; they also relate to the supports thus produced and the uses which can be made of such a support.
- adsorption technique In this case, proteins can be adsorbed on a support by several routes of interaction (1). The main ones are hydrophobic, polar and ionic interactions. These interactions are a function of the support, the protein and the medium considered.
- Hydrophobic adsorption is carried out by an adsorption method on a plane silica support used in the laboratory (2) which uses the interactions between a silanized surface with long alkyl chains and one or more hydrophobic zones of the protein.
- patent application EP-A-0.874.242 concerns the silanization of a support (silica oxide) on which biological molecules can be fixed completely randomly. The fixing takes place in several stages. First, the activation of silanols by hydrolysis of the oxygen bridges. Second, the bond between the silanols and an intermediate binding molecule, which can receive a ligand.
- Patent application EP-A-0,272,792 has substantially the same drawbacks as the application described above, since it proposes to fix, always in a random manner, antigens on particles.
- there is a second intermediate stage which consists in the supply of cyanogen bromide which, by covalent bonds, will indirectly associate the particles and the antigens.
- EP-A-0.874.242 and EP-A-0.272.792 are therefore very far from one of the main objectives of the present invention. This objective consists in the orientation of the biological molecules fixed on the support.
- a biological molecule can also be selectively fixed by chelation on a support, according to a principle known to those skilled in the art, such as that used for the purification of proteins by the IMAC process (Immobilized Metal ion-Affinity Chromatography) on resins (3, 4).
- IMAC process Immobilized Metal ion-Affinity Chromatography
- Such a protein has a marking, called "tag”, rich in histidines.
- the difficulty of the method consists in generating a support having divalent ions necessary for chelation. Such an approach is described in the patent application, filed on April 16, 1997 under the number FR97 / 04923 by the applicant.
- a method of fixing biological material makes it possible to optimize the complexation of this material with a metal complex, while reducing, or even eliminating, any secondary reaction of adsorption of said material on the metal complex.
- the method for fixing a biological material of the invention uses a coordinating ligand compound, or a complex compound obtained starting from the latter, said ligand compound being in microparticulate form or in linear form and consisting of at least one particulate or linear polymer, with an apparent hydrophilic surface, and free complexing groups, fixed in a covalent manner.
- the object of the present invention is to allow the attachment of a biological molecule, such as a recombinant protein derived from an antigen, an antibody, an enzyme, but also synthetic peptides and PNA (peptide nucleic acids) on silica or metal oxide supports.
- a biological molecule such as a recombinant protein derived from an antigen, an antibody, an enzyme, but also synthetic peptides and PNA (peptide nucleic acids) on silica or metal oxide supports.
- This immobilization uses interactions between the silanols of the silica or the alcohol functions of the metal oxides and a specific zone of the protein.
- the particular properties of the biospecific support thus created are mainly a good orientation of the biological molecules or ligands on the surface and a support generating very good signal to background noise ratios.
- this type of immobilization is simple and stable over time.
- the present invention relates to a process for fixing a biological molecule to the surface of a support consisting of silic
- the method comprises, before contacting, a step of immersing the functionalized surface in a sulfochromic mixture.
- the specific binding site of the biological molecule has the following characteristics:
- this sequence is introduced in a privileged place of the original sequence where it is exposed in a relevant manner with regard to its function or its properties, and - It contains in particular amino acids of interest vis-à-vis the desired function.
- the specific binding site of the biological molecule is a site rich in histidines and its derivatives, such as a site containing a sufficient density of histidines, in particular greater than or equal to 25%, and preferably greater or equal to 33%).
- the biological molecule and the specific binding site constitute a recombinant protein comprising at least two adjacent histidines, called "tags".
- the specific binding site of the biological molecule comprises at least four histidines, and preferably six adjacent histidines.
- the specific site is located within the recombinant protein or preferably at its N-terminal or C-terminal end.
- the contacting takes place for 30 to 60 minutes.
- the contacting takes place for 45 minutes.
- the immersion step is carried out for 5 to 30 minutes.
- the immersion step is carried out for 15 minutes.
- the process is carried out at an optimal hydrogen potential (pH) as a function of the physico-chemical characteristics of the biological molecule and of the specific binding site, preferably between 6 and 7.5.
- the present invention also relates to a surface of a support functionalized by the method described above.
- the surface is flat.
- the surface is constituted by a ball.
- the present invention also relates to the use of a functionalized surface of a support, as described above, or manufactured by the method, described above, characterized in that it consists in carrying out tests to detect, in a liquid to be analyzed, the presence of any biological molecule capable of fixing, by a specific binding site, on the support.
- a functionalized surface of a support is used to carry out immunological tests to detect, in a liquid to be analyzed, the presence of antibodies specific for a natural protein, for example the P24 protein, by specific binding, in the same way as with the natural protein, on at least one recombinant protein, for example the RH24 or R24 protein.
- This protein P24 is a recombinant protein of the capsid of the human immunodeficiency virus type 1 (HTV-1).
- HTV-1 human immunodeficiency virus type 1
- FIG. 1 represents a comparative graph of the optical density (OD) obtained on an ELISA test of RH24 (B) and R24 (D) absorbed on different supports:
- FIG. 2 represents a comparative graph of the signal / noise coefficient of the protein system absorbed RH24 and R24 on different supports:
- FIG. 3 represents a curve of the effect of pH on the absorption of RH24 on silica.
- FIG. 4 represents a curve for assaying the 15F8C7 monoclonal antibodies by SFMIA (Scanning Force Microscopic ImmunoAssay); R24 (- • -) and RH24 (- ⁇ -).
- FIG. 5 represents a curve for assaying rabbit polyclonal antibodies by SFMIA; R24 (- • -) and RH24 (- ⁇ -) and
- a plane support of silicon oxide or silica and a recombinant protein of the capsid of the human immunodeficiency virus type 1 (VTH-1) are used as a model.
- This system allows the use of atomic force microscopy (AFM) as a method of immunological analysis or SFMIA (2).
- AFM atomic force microscopy
- the protein considered here is RH24. It is obtained using the conventional methods of molecular biology and eukaryotic expression (5). This is almost similar to R24 (identical immunogenicity) but is much more easily purified thanks to the presence of a small sequence of additional amino acids. This series of amino acids, called "tag", contains in particular six consecutive histidines. The affinity of such a molecular motif for certain metal ions is extremely strong. This property allows easy purification with the IMAC technique (metal-chelate affinity chromatography).
- the control protein without the "tag” is R24. It is obtained in the same way as RH24 but it is purified by immunoaffinity.
- the specific binding sites can be in the form of sequences of said amino acids, identical or different, contiguous or not, but neighboring.
- this sequence is introduced in a privileged place of the original sequence where it is exposed in a relevant manner with respect to its function (or its properties, for example chelation, coupling, interactions with a particular support, etc.), in particular the N-terminal and C-terminal ends of the recombinant proteins or synthetic peptides or PNAs, and
- histidines contains in particular amino acids of interest with respect to the desired function, in our case histidines, distributed within the sequence either contiguously (in particular two contiguous histidines, preferably six contiguous histidines) , or with a sufficient density (in particular 25%, preferably greater than or equal to 33%).
- said binding site comprises from three to ten amino acids, contiguous or non-contiguous, for an ordered primary structure of the protein material comprising at least thirty amino acids.
- it consists of at least two, preferably at least three, and preferably at least six histidine residues, more particularly, these residues are contiguous.
- the site (s) described above can be found anywhere in the primary structure of the protein material. Preferably, it is located on the N-terminal or C-terminal end of the protein material.
- Silica available in many forms (flat surfaces, beads, fibers, etc.), is a compound widely used in microelectronics.
- research in medical diagnosis is increasingly interested in so-called systems
- Atomic force microscopy carries out the observation of surfaces functionalized by biological molecules as well as very sensitive immunoassays (2). It has been found that RH24 has a natural affinity for silica supports. This property comes from a strong direct interaction between the surface of a support and the poly (histidine) sequence.
- the present invention therefore aims to fix a recombinant protein on silica via its histidine sequence. This technique also makes it possible to orient such a protein on the surface. Indeed, if the exposed area of the molecule is a recognition site, then this is all the more reactive (active site of enzyme or immunodominant epitope for example).
- the invention relates to the oriented binding of RH24 and of any recombinant protein on silica. It therefore fits into this trend.
- Complete information on the R24 protein and its recombinants RH24 and RH24K can be found in a previous patent application of the applicant, filed on June 20, 1997 under the number FR97 / 08055. The content of this application is incorporated into the present invention.
- the invention relates to a direct fixation route, without silanization of the silica, to allow the binding between the silica and the recombinant protein.
- the approach uses the specific affinity of the RH24 “tag” for hydrophilic silica. This fastening technique is new and extremely simple and robust. It is the object of the protection sought by the present invention.
- the advantage of this immobilization according to the second approach is to be found in two major techniques, on the one hand, the ELISA for its simplicity and its robustness, and on the other hand, the immunological assay by AFM (SFMIA) for its finesse and his sensitivity.
- Example 1 Manufacturing of the biospecific support:
- the supports used here are silicon discs (polished 4 "disc from ACM (France), type N doped P, thickness 525 micrometers ( ⁇ m), orientation ⁇ 100>)
- the cleaved plates have, on their surface, a layer of silicon oxide, native or obtained by the various methods known to those skilled in the art.
- This oxide layer has, among other things, hydrophobic siloxane bridges and it can be polluted by atmospheric contaminants.
- Silica of this type is partially hydrophobic.
- the plates undergo the following treatment: - surface cleaning: the silicon plates are washed with various solvents; in order are used: water, ethanol, acetone, dichloromethane, toluene, and
- the silica supports are immersed for 15 minutes in a sulfochromic mixture (PROLABO solution saturated with Chromium (VI) oxide in 95% sulfuric acid). These surfaces are thoroughly rinsed with water and passed through an ultrasonic bath; once the plates have been dried with nitrogen, they are used quickly to limit rapid recontamination.
- a sulfochromic mixture PROLABO solution saturated with Chromium (VI) oxide in 95% sulfuric acid
- the main characteristic of a clean silica is its high hydrophilicity. This can be checked by measuring the contact angle (angle between the tangent at the edge of the drop of water and the surface of the support) which must be less than or equal to 10 °. 3) Hydrophobic silica:
- the plates are cleaned as described above (paragraph 2).
- the silica is made hydrophobic by contacting n-octadecyl-dimethylmethoxysilane, silane carrying a long alkyl chain, at 2% in toluene for three hours at room temperature. The plates are then washed thoroughly with water, cleaned with ultrasound and stabilized for two hours at 120
- RH24 has a strong affinity for silica.
- the interest of this affinity is its specificity towards RH24 in comparison with R24. From this point, the following analysis attempts to better understand the role of the "tag”.
- R24 and RH24 are revealed by two types of immunoassays: ELISA and SFMIA.
- R24 or RH24 on the surface of the support is evaluated by means of antico ⁇ s.
- Polyclonal or monoclonal solutions are used.
- a drop of 40 ⁇ l of antico ⁇ s in solution in the PBS-TWEEN-BSA mixture [0.05% BSA (w / w) in PBS-TWEEN] of desired concentration is deposited for 1 hour at 37 ° C. on a plate.
- the BSA allows, like TWEEN, to limit non-specific interactions.
- the silicon square is then washed with PBS-TWEEN-BSA in order to eliminate as much as possible the antibodies adsorbed on the support and not fixed on the protein.
- the plates are dried with compressed air.
- Enzymatic test The amount of biotinylated antico ⁇ s, captured by the recombinant protein, is evaluated by an enzymatic test.
- An alkaline phosphatase (PAL) - Streptavidin complex is attached first. For this, 40 ⁇ l of a solution of Streptavidin-PAL at 4 g / ml in PBS-TWEEN-BSA are reacted at 37 ° C. for 45 minutes. 10
- pnPP p-nitophenyl phosphate
- SFMIA test The amount of biotinylated antibodies, captured by the recombinant protein, on the support is evaluated using a topographic AFM marker:
- the number of magnetic beads on the surface is proportional to the quantity of proteins retained on the support. This number of beads is quantified by AFM.
- this support makes it possible to obtain an excellent signal / noise coefficient. This is probably due to the fact 11 that the adsorption of antico ⁇ s is done little on a hydrophilic support (the Fc of the antibodies is rather hydrophobic).
- RH24 for silica is remarkable because it is very little sensitive to the ionic strength of the surrounding medium. Thus, rinsing with water or with a Nal 9 M solution has no effect on the surface. The RH24 once fixed is therefore strongly linked to the support.
- RH24 was diluted to 1 ⁇ g / ml in different phosphate buffers whose pH varies between 4 and 11. Then it is adsorbed and revealed by a standard ELISA test with rabbit polyclonal at 1 ⁇ g / ml.
- the optimal adsorption conditions obtained are between 6 and 7 (see Figure 3).
- the signal decreases by more than 85% in the presence of the polypeptide, which suggests that the sequence, occupying the binding sites prevents RH24 from binding to its support.
- the sensitivity of the RH24 detection system on a silica support is evaluated using an SFMIA.
- a protein solution at 10 ⁇ g / ml is incubated on plates. These plates are revealed by SFMIA using polyclonal and monoclonal antico ⁇ s (15F8C7) marked with magnetic particles. The quantity of magnetic beads covering the surface is evaluated using the image processing system. The percentage recovery curves as a function of the concentration of antibodies used are thus plotted in FIGS. 4 and 5.
- RH24 Since the monoclonals used are not directed against the “tag”, they intrinsically have the same reactivity with respect to R24 and to RH24.
- the signal increase for RH24 can result from two phenomena.
- RH24 is more concentrated surface than R24, or RH24 is oriented on its support. If RH24 is partially oriented on its support, then the binding epitope of the monoclonal antibody is more frequently accessible.
- the epitope recognized by the monoclonal is ALWAYS accessible or NEVER, whereas in the case of a RANDOM FIXATION, it will only be accessible SOMETIMES. This therefore results in an increase in the immunoassay signal on this monoclonal. This amplification of the signal will not take place with a polyclonal on RH24 because this does not have an immunodominant epitope. Orienting such a protein on a support is therefore of no interest for a polyclonal solution.
- the immobilization obtained is not very sensitive to variations in ionic strength and retains its immunogenic properties over a long period.
- this support gives much better signal / noise ratios than a system by adsorption on a hydrophobic support.
- Standard enzymatic assays for anti-R24 antibodies are usually performed on supports (polystyrene well) where the protein is adsorbed by hydrophobic interactions.
- the detection limits obtained by adsorption on hydrophilic silica are comparable to these immunoassays.
- the planar support used lends itself to the use of atomic force microscopy.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69920427T DE69920427T2 (de) | 1998-04-10 | 1999-04-12 | Befestigung eines biologischen moleküls auf der öberflache eines trägers |
CA002328302A CA2328302A1 (fr) | 1998-04-10 | 1999-04-12 | Fixation d'une molecule biologique sur une surface d'un support |
AT99913389T ATE277350T1 (de) | 1998-04-10 | 1999-04-12 | Befestigung eines biologischen moleküls auf der öberflache eines trägers |
JP2000543832A JP4443764B2 (ja) | 1998-04-10 | 1999-04-12 | 生物学的分子を支持体表面に固定する方法 |
EP99913389A EP1070256B1 (fr) | 1998-04-10 | 1999-04-12 | Fixation d'une molecule biologique sur une surface d'un support |
US09/647,983 US6660533B2 (en) | 1998-04-10 | 1999-04-12 | Attaching a biological molecule to a support surface |
AU31528/99A AU758648B2 (en) | 1998-04-10 | 1999-04-12 | Method for fixing a biological molecule on a support surface |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR98/04879 | 1998-04-10 | ||
FR9804879A FR2777355B1 (fr) | 1998-04-10 | 1998-04-10 | Procede de fixation d'une molecule biologique sur la surface d'un support constitue de silice ou d'oxyde metallique |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999053321A1 true WO1999053321A1 (fr) | 1999-10-21 |
Family
ID=9525404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/000848 WO1999053321A1 (fr) | 1998-04-10 | 1999-04-12 | Fixation d'une molecule biologique sur une surface d'un support |
Country Status (9)
Country | Link |
---|---|
US (1) | US6660533B2 (fr) |
EP (1) | EP1070256B1 (fr) |
JP (1) | JP4443764B2 (fr) |
AT (1) | ATE277350T1 (fr) |
AU (1) | AU758648B2 (fr) |
CA (1) | CA2328302A1 (fr) |
DE (1) | DE69920427T2 (fr) |
FR (1) | FR2777355B1 (fr) |
WO (1) | WO1999053321A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011106451A1 (fr) * | 2010-02-23 | 2011-09-01 | Life Technologies Corporation | Procédés de traitement de surfaces d'oxyde métallique, et surfaces obtenues par ces procédés |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9425138D0 (en) | 1994-12-12 | 1995-02-08 | Dynal As | Isolation of nucleic acid |
DE60015360T9 (de) * | 2000-11-20 | 2005-12-15 | Sony International (Europe) Gmbh | Verfahren zur Immobilisierung von Nukleinsäuren auf festem Träger |
FR2827799A1 (fr) * | 2001-07-27 | 2003-01-31 | Sofradim Production | Endoprothese vasculaire recouverte d'un derive fonctionnalise de dextrane et son procede de preparation |
US6802966B2 (en) * | 2001-08-14 | 2004-10-12 | W. R. Grace & Co. Conn. | Solid compositions for selective adsorption from complex mixtures |
US6987079B2 (en) | 2001-08-14 | 2006-01-17 | W.R. Grace & Co.-Conn. | Supported catalyst systems |
CA2473376A1 (fr) | 2002-01-16 | 2003-07-31 | Dynal Biotech Asa | Methode permettant d'isoler des acides nucleiques et des proteines contenus dans un echantillon unique |
GB0229287D0 (en) * | 2002-12-16 | 2003-01-22 | Dna Res Innovations Ltd | Polyfunctional reagents |
US7488607B2 (en) * | 2003-09-30 | 2009-02-10 | Agilent Technologies, Inc. | Electronically readable microarray with electronic addressing function |
CN1938224B (zh) * | 2004-03-30 | 2011-03-30 | 东洋先进机床有限公司 | 基材表面处理方法及处理了表面的基材、医疗材料和器具 |
US7217428B2 (en) * | 2004-05-28 | 2007-05-15 | Technology Innovations Llc | Drug delivery apparatus utilizing cantilever |
WO2007055288A1 (fr) * | 2005-11-10 | 2007-05-18 | National University Of Corporation Hiroshima University | Procede et agent destines a l'immobilisation d'une proteine par fixation de celle-ci sur une substance contenant de la silice |
DE102006051482A1 (de) * | 2006-07-31 | 2008-02-14 | Nikolaus Bartels | Anordnung zum Erfassen von Substanzen, Herstellung der Anordnung und ihre Verwendung |
AU2007323594A1 (en) * | 2006-11-21 | 2008-05-29 | Applied Biosystems, Llc | Intermediates and methods for forming passivated surfaces on oxide layers and articles produced thereby |
US8173198B2 (en) * | 2008-07-23 | 2012-05-08 | Life Technologies Corporation | Deposition of metal oxides onto surfaces as an immobilization vehicle for carboxylated or phophated particles or polymers |
EP2380026B1 (fr) * | 2008-12-22 | 2016-03-23 | Koninklijke Philips N.V. | Essai pour la troponine i à l'aide des marqueurs magnétiques |
JP2020124129A (ja) * | 2019-02-01 | 2020-08-20 | 積水化学工業株式会社 | 核酸の単離方法及び核酸単離用デバイス |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0272792A1 (fr) * | 1986-11-21 | 1988-06-29 | Imre Corporation | Enlèvement antigène-spécifique des immunocomplexes circulant |
EP0368208A2 (fr) * | 1988-11-07 | 1990-05-16 | SANYO CHEMICAL INDUSTRIES, Ltd. | Méthode d'assai immunologique et trousse d'essai |
WO1991002980A1 (fr) * | 1989-08-24 | 1991-03-07 | Ramsey Foundation | Procede et appareil de mesure d'antigenes organiques |
EP0482571A1 (fr) * | 1990-10-22 | 1992-04-29 | Sumitomo Electric Industries, Ltd. | Essai de substances utilisant cytometrie en flux |
US5492814A (en) * | 1990-07-06 | 1996-02-20 | The General Hospital Corporation | Monocrystalline iron oxide particles for studying biological tissues |
EP0874242A1 (fr) * | 1997-04-21 | 1998-10-28 | Randox Laboratories Ltd. | Dispositif et appareil pour la détection simultanée de plusieurs analytes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6035263A (ja) * | 1983-08-05 | 1985-02-23 | Wako Pure Chem Ind Ltd | 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬 |
GB2221466A (en) * | 1988-03-09 | 1990-02-07 | Aluminum Co Of America | Biologically reactive particles with biological, therapeutic and chromatographic applications |
US5627079A (en) * | 1989-03-27 | 1997-05-06 | The Research Foundation Of State University Of New York | Refunctionalized oxyfluorinated surfaces |
US6020026A (en) * | 1997-01-17 | 2000-02-01 | Corning Incorporated | Process for the production of a coating of molecular thickness on a substrate |
FR2758884B1 (fr) | 1997-01-30 | 1999-04-02 | Bio Merieux | Procede pour isoler, notamment detecter ou quantifier un analyte dans un milieu |
FR2762394B1 (fr) | 1997-04-16 | 1999-05-28 | Bio Merieux | Compose ligand de coordination et utilisation pour fixer un materiel biologique |
FR2764988B1 (fr) | 1997-06-20 | 1999-07-23 | Bio Merieux | Compose conjugue, reactif et kit le contenant, et utilisations dans un procede de fixation d'un materiel biologique |
US6207391B1 (en) * | 1998-03-31 | 2001-03-27 | Tularik Inc. | High-throughput screening assays for modulators of STAT4 and STAT6 activity |
-
1998
- 1998-04-10 FR FR9804879A patent/FR2777355B1/fr not_active Expired - Lifetime
-
1999
- 1999-04-12 WO PCT/FR1999/000848 patent/WO1999053321A1/fr active IP Right Grant
- 1999-04-12 AT AT99913389T patent/ATE277350T1/de not_active IP Right Cessation
- 1999-04-12 EP EP99913389A patent/EP1070256B1/fr not_active Expired - Lifetime
- 1999-04-12 JP JP2000543832A patent/JP4443764B2/ja not_active Expired - Fee Related
- 1999-04-12 US US09/647,983 patent/US6660533B2/en not_active Expired - Lifetime
- 1999-04-12 AU AU31528/99A patent/AU758648B2/en not_active Ceased
- 1999-04-12 DE DE69920427T patent/DE69920427T2/de not_active Expired - Lifetime
- 1999-04-12 CA CA002328302A patent/CA2328302A1/fr not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0272792A1 (fr) * | 1986-11-21 | 1988-06-29 | Imre Corporation | Enlèvement antigène-spécifique des immunocomplexes circulant |
EP0368208A2 (fr) * | 1988-11-07 | 1990-05-16 | SANYO CHEMICAL INDUSTRIES, Ltd. | Méthode d'assai immunologique et trousse d'essai |
WO1991002980A1 (fr) * | 1989-08-24 | 1991-03-07 | Ramsey Foundation | Procede et appareil de mesure d'antigenes organiques |
US5492814A (en) * | 1990-07-06 | 1996-02-20 | The General Hospital Corporation | Monocrystalline iron oxide particles for studying biological tissues |
EP0482571A1 (fr) * | 1990-10-22 | 1992-04-29 | Sumitomo Electric Industries, Ltd. | Essai de substances utilisant cytometrie en flux |
EP0874242A1 (fr) * | 1997-04-21 | 1998-10-28 | Randox Laboratories Ltd. | Dispositif et appareil pour la détection simultanée de plusieurs analytes |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011106451A1 (fr) * | 2010-02-23 | 2011-09-01 | Life Technologies Corporation | Procédés de traitement de surfaces d'oxyde métallique, et surfaces obtenues par ces procédés |
Also Published As
Publication number | Publication date |
---|---|
DE69920427D1 (de) | 2004-10-28 |
US6660533B2 (en) | 2003-12-09 |
JP2002511587A (ja) | 2002-04-16 |
FR2777355A1 (fr) | 1999-10-15 |
FR2777355B1 (fr) | 2000-05-12 |
EP1070256B1 (fr) | 2004-09-22 |
JP4443764B2 (ja) | 2010-03-31 |
ATE277350T1 (de) | 2004-10-15 |
AU758648B2 (en) | 2003-03-27 |
AU3152899A (en) | 1999-11-01 |
DE69920427T2 (de) | 2006-02-09 |
US20030082658A1 (en) | 2003-05-01 |
EP1070256A1 (fr) | 2001-01-24 |
CA2328302A1 (fr) | 1999-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1070256B1 (fr) | Fixation d'une molecule biologique sur une surface d'un support | |
EP2901160B1 (fr) | Méthode pour détecter spécifiquement dans un echantillon une métalloprotéase matricielle (mmp) d'intérêt uniquement dans sa forme active | |
JP5388462B2 (ja) | 担体及びその製造方法 | |
EP2470907B1 (fr) | Proteines utilisees pour le diagnostic d'une borreliose de lyme | |
EP4341387A1 (fr) | Proteines de liaison au recepteur d'un bacteriophage et leurs utilisations | |
CA2148268A1 (fr) | Methode d'immunodosage specifique de la glutathion peroxydase plasmatique humaine | |
WO2009115756A2 (fr) | Procede de detection directe de l'albumine modifiee de l'ischemie par utilisation d'un partenaire de liaison a un derive aldehyde issu de la peroxydation de lipides sous forme liee | |
EP2470908B1 (fr) | Proteines utilisees pour le diagnostic d'une borreliose de lyme | |
Falipou et al. | New use of cyanosilane coupling agent for direct binding of antibodies to silica supports. Physicochemical characterization of molecularly bioengineered layers | |
WO2001051927A1 (fr) | Procede d'immobilisation de reactif(s) affin(s) sur phase solide hydrophobe | |
BE1028465B1 (fr) | Test de detection rapide serologique de l'infection covid-19 | |
EP1395825B1 (fr) | Procede de detection d'auto-anticorps specifiques de la polyarthrite rhumatoide | |
EP2705368B1 (fr) | Utilisation de ef-1 et de ses homologues, pour detecter une proteine retrovirale p24 ou un homologue de celle-ci | |
Jane et al. | Porous silicon biosensor for the detection of auto-immune diseases | |
EP3420358A1 (fr) | Peptides immunogenes et leur utilisation | |
KR20180106380A (ko) | 폴리도파민과 단백질 g의 혼합용액으로 개질된 코팅층을 포함하는 바이오센서 및 상기 바이오센서를 이용한 생물시료의 검출 방법 | |
FR2857453A1 (fr) | Procede de detection serologique de la maladie coeliaque et necessaire de diagnostic associe | |
WO2004083370A2 (fr) | Methode de detection et d'analyse d'organelles immobilises sur biopuce et leurs applications | |
WO2003044533A2 (fr) | Phase de capture et de detection d'un materiel biologique cible pour des tests elisa | |
FR2847983A1 (fr) | Dispositif miniature de detection electrique d'interactions de type ligand-recepteur, preparation et utilisations. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09647983 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999913389 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2328302 Country of ref document: CA Ref country code: CA Ref document number: 2328302 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 31528/99 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1999913389 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 31528/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999913389 Country of ref document: EP |